Phase II single-arm study of a combination of obinutuzumab and venetoclax in early relapsed or refractory diffuse large B-cell lymphoma—final results of the AGMT NHL15B study

Phase II single-arm study of a combination of obinutuzumab and venetoclax in early relapsed or refractory diffuse large B-cell lymphoma—final results of the AGMT NHL15B study

BackgroundPatients with diffuse large B-cell lymphoma (DLBCL) relapsing early (within 12 months) or primary refractory to induction therapy with rituximab (R) and CHOP have a poor prognosis. We therefore initiated a study with obinutuzumab and venetoclax.Study design and methodsTwenty-one patients w...

Full description

Bibliographic Details
Main Authors: Ulrich Jaeger, Ingrid Simonitsch-Klupp, Patrick Klammer, Alexander Egle, Sonja Heibl, Peter Neumeister, Ella Willenbacher, Florian Erlsbacher, Julian Larcher-Senn, Philipp B. Staber, Edit Porpaczy, Cathrin Skrabs, Marius E. Mayerhoefer, Marcus Hacker, Thomas Melchardt, Michael A. Fridrik, Richard Greil
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Hematology
Subjects:
diffuse large B-cell lymphoma
early relapsed or refractory
obinutuzumab
venetoclax
chemo-free
Online Access:https://www.frontiersin.org/articles/10.3389/frhem.2024.1331008/full

Internet

https://www.frontiersin.org/articles/10.3389/frhem.2024.1331008/full

Similar Items